Impact Factor 2020 : 11.000
Nos revues
| Status | Stage |
|---|---|
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
- Altered fractionation of thoracic radiation therapy for localised small cell lung cancer
- Anti-angiogenic therapy for lung cancer
- Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol
- Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis
- Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer
- Chemotherapy and surgery versus surgery alone in non-small cell lung cancer
- Chemotherapy for advanced non-small cell lung cancer in the elderly population
- Chemotherapy for brain metastases from small cell lung cancer
- Chemotherapy for non-small cell lung cancer
- Chemotherapy versus best supportive care for extensive small cell lung cancer
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
- Concurrent chemoradiotherapy in non-small cell lung cancer
- Consolidative thoracic radiotherapy for extensive disease small cell lung cancer
- Drugs for preventing lung cancer in healthy people
- Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer
- Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR
- Exercise training for advanced lung cancer
- Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer
- First-line systemic treatment for people with extensive-stage small cell lung cancer: a systematic review and network meta-analysisNew
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
- Gabapentinoids for chronic post-thoracotomy pain after lung surgery in adults
- Gefitinib for advanced non-small cell lung cancer
- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer
- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer
- Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent
- Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality
- Interventions for smoking cessation in people diagnosed with lung cancer
- Limited resections versus lobectomy for stage I non-small cell lung cancer
- Non-invasive interventions for improving well-being and quality of life in patients with lung cancer
- Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
- Palliative endobronchial brachytherapy for non-small cell lung cancer
- Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer
- Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
- PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer
- Platinum versus non-platinum chemotherapy regimens for small cell lung cancer
- Postoperative radiotherapy for non-small cell lung cancer
- Preoperative exercise training for people with non-small cell lung cancer
- Prophylactic cranial irradiation for extensive-stage small cell lung cancer
- Prophylactic cranial irradiation for patients with limited-stage small cell lung cancer
- Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer
- Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma
- Radical multimodality therapy for malignant pleural mesothelioma
- Radiotherapy for malignant pleural mesothelioma
- Screening for lung cancer
- Second-line chemotherapy for non-small cell lung cancer
- Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
- Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis
- Surgery for limited-stage small-cell lung cancer
- Surgery for local and locally advanced non-small cell lung cancer
- Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer
- Surgical sealant for preventing air leaks after pulmonary resections in patients with lung cancer
- Targeted therapy for advanced anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer
- Taxanes for advanced non-small cell lung cancer
- Therapeutic vaccines for advanced non-small cell lung cancerNew
- Third-line systemic chemotherapy for small cell lung cancer
- Third-line systemic treatment for non-small cell lung cancer
- Video-assisted thoracoscopic lobectomy versus open thoracotomy conventional lobectomy for stage I non-small cell lung cancer
- Diagnosis (1)
- Prevention (all lung cancer) (2)
- Occupational protection (0)
- Environmental protection (0)
- Chemoprevention (1)
- Tobacco avoidance, including passive smoking (covered by the Tobacco Addiction Group) (0)
- Others (1)
- Early detection (all lung cancer) (4)
- Blood test (0)
- Radiology (1)
- Sputum Cytology (1)
- Computerized Tomography (CT) (2)
- Magnetic Resonance Imaging (MRI) (0)
- Bronchoscopy (0)
- Treatment (67)
- NSCLC (44)
- Immunotherapy (2)
- Surgery (5)
- Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis
- Preoperative exercise training for people with non-small cell lung cancer
- Limited resections versus lobectomy for stage I non-small cell lung cancer
- Surgery for local and locally advanced non-small cell lung cancer
- Video-assisted thoracoscopic lobectomy versus open thoracotomy conventional lobectomy for stage I non-small cell lung cancer
- Chemotherapy (18)
- Gefitinib for advanced non-small cell lung cancer
- Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
- Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol
- Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
- Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer
- Chemotherapy for non-small cell lung cancer
- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
- Chemotherapy for advanced non-small cell lung cancer in the elderly population
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer
- Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol
- Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
- Second-line chemotherapy for non-small cell lung cancer
- Targeted therapy for advanced anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer
- Taxanes for advanced non-small cell lung cancer
- Third-line systemic treatment for non-small cell lung cancer
- Radiotherapy (7)
- Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol
- Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis
- Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer
- Palliative endobronchial brachytherapy for non-small cell lung cancer
- Postoperative radiotherapy for non-small cell lung cancer
- Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis
- Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer
- Combined modality therapy (10)
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
- Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol
- Concurrent chemoradiotherapy in non-small cell lung cancer
- Therapeutic vaccines for advanced non-small cell lung cancerNew
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent
- Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR
- Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol
- Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
- Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer
- Chemotherapy and surgery versus surgery alone in non-small cell lung cancer
- Holistic/complementary/non-invasive therapies (2)
- SCLC (11)
- Surgery (1)
- Chemotherapy (5)
- Platinum versus non-platinum chemotherapy regimens for small cell lung cancer
- Chemotherapy versus best supportive care for extensive small cell lung cancer
- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer
- Chemotherapy for brain metastases from small cell lung cancer
- Third-line systemic chemotherapy for small cell lung cancer
- Radiotherapy (4)
- Altered fractionation of thoracic radiation therapy for localised small cell lung cancer
- Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer
- Prophylactic cranial irradiation for extensive-stage small cell lung cancer
- Prophylactic cranial irradiation for patients with limited-stage small cell lung cancer
- Combined modality therapy (0)
- Holistic/complementary/non-invasive therapies (0)
- immunotherapy (1)
- All lung cancer (7)
- Surgery (2)
- Chemotherapy (1)
- Radiotherapy (0)
- Combined modality therapy (1)
- Holistic/complementary/non-invasive therapies (3)
- Mesothelioma (5)
- Immunotherapy (0)
- Surgery (0)
- Chemotherapy (2)
- Radiotherapy (3)
- NSCLC (44)